COYA Coya Therapeutics Inc

$COYA $GANX Top 2 picks in small bio still flying under the radar...but on the verge of national recognition and acknowledgement in my mind. Both high probability acquisitions, at least one by year end and the other likely not long after...Just my speculative personal thoughts. Added to both recently. Stay the course X2...

$COYA $GANX Going to be interesting to see what both do by Xmas. Best speculative guess is COYA is right around $10 and GANX where COYA is right now at $5. Things can change in a split second. Bet anyone here that proverbial beer that at least one has a new name on the door in Jan, and the other still standing follows soon in the same footsteps.

$COYA $GANX $RDY “In the 12 evaluable participants, MDS-UPDRS motor scores were stable over the 12-month study period with rexaceract, demonstrating no clinically meaningful progression of motor symptoms” SCREAMING BUY AT $1.60/$1.70

$COYA BUY Ratings within the last few months 🔵👍 H.C. Wainwright — Buy — $18 price target August 24 Reiterated Buy with the highest recent target at $18. H.C. Wainwright highlighted the ongoing ALSTARS Phase 2 ALS program and upcoming pipeline milestones. 🔵👍 Roth Capital / Roth MKM — Buy — $12 price target August 23–24 Reiterated Buy and maintained its $12 target. 🔵👍 Freedom Broker — Buy — $15.50 price target August 17 Reiterated Buy with a $15.50 target. cited COYA's $43.2 million cash position and runway into H2 2027, potentially carrying the company through the important ALSTARS Q1 2027 readout. 🔵👍 Chardan Capital — Buy — $14 price target August 12 Maintained Buy and an unchanged $14 target following Coya's Q2 update. 🔵👍 Lake Street Capital — Buy — $17 price target August 11 Reiterated Buy with a $17 target. valuation was driven by the economics of COYA 302 in ALS, including Coya's royalties 🔵👍 BTIG — Buy — $16 price target Date: August 11, 2026

$COYA From Encode Ideas note... In our view, this makes Dr. Reddy's involvement far more compelling than a standard licensing arrangement. If ALSTARS yields positive results, consider their strategic positioning: they retain ALS commercial rights across most primary markets, produce one of the therapy's core components, maintain a 9.7% equity stake, and are obligated to pay royalties on all sales and to make several hundred million dollars in milestone payments. Consequently, when you consider who will be at the negotiating table with strong data, the answer is clear—they are already seated there. $BMY $RDY

$COYA No one is talking about the Bruce Willis disease FTD...THERE Is no treatment for FTD in the world...$COYA DID A SMALL STUDY ON 9 PATIENTS....STOPPED AND HALTWD IN ALL 9 PATIENTS!!!! This the same mechanism as ALS so when our combinational therapy works FTD WILL AS WELL!!!!!!! FTD is 2x to 3x patient volume....significantly longer treatment duration... FTD IS WORTH 4.5B TO 6B VS ALS 1.5B TO 2.5B..... When $COYA succeeds and gets approved in 18 to 20 months.....we have FTD ready to roll... MOST IMPORTANTLY WE ALL SHOULD FEEL THAT WE ALL CONTRIBUTED HERE HELPING OUR BROTHERS AND SISTERS FINALLY GETTING QUALITY OF LIFE!!! HEALTH B4 WEALTH!!!!

$COYA $GANX Good stuff! I love making disciplined risk on trades. Gain is extremely interesting and added a lot more last week. Need to open the hood on Coya as it looks very compelling.

$COYA Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS Oct 05, 2026 120th participant has been enrolled in ALSTARS trial achieving target enrollment Additional eligible participants already in active screening will be allowed to enroll Topline data from 24-week double-blind treatment phase on track for early Q2 2027

$COYA 3.5 years later still games...until its not.... This will be the astandard of care in 20 months...Give people real hope! It will work!!! Too many smart minds here... ITS TIME

$COYA The company has said that Proteomics will be coming in the 2nd half of the year. In my opinion the NEALS conference is coming up Oct 27th to October 30th. I believe there is a possibility the data is presented there. If you recall we had the longitudal study come out April 9th $COYA was approx $4.08 by April 20th it ran to $4.99 up 23%. Keep in mind this readout was on 3 proteins Nfl...Hne..and LBP. The proteomics readout is thousands if plasma proteins. In layman's terms if the April data showed that the frug can turn off some bad switches, the new PROTEOMICS data proves it can rewire the entire biilogical circuit making it a significantly stronger, higher conviction CATALYST. BOTTOM LINE: Longitudinal study 8 DAYS moved $COYA 23% PROTEOMICS will move us to $7. This is very SIGNIFICANT for us.

$COYA Looking at the October deck this slide should make it pretty obvious what happens before any ALS trial data comes out. Dr Reddys will need to buy them before that as they have too much at stake not to.

$COYA I went back through my archives to look at the original n=4 data. At a year there was not any progression. While the number is small the current study is screening out to get the right candidates that could respond better. Keep in mind the original drug approved, Relyvrio, barely slowed progression and was approved. Our data shows no progression. Obviously doing it in the 120 patient study is the key but the original 4 patient data is relevant. Along with the fact they have had years to get to this point. Years ago when I first talked to them I was very skeptical but over the years I have gotten a high confidence in people like Dr Appel who have made this his lifes work.

$COYA Chart is indicating a Golden Cross is very close to occuring. It i sviewed as a Positive SignalConfirmation of a Trend Reversal: Stock prices fluctuate daily. A golden cross filters out this short-term "noise." When the 50-day average overtakes the 200-day average, it proves that recent buying pressure is strong enough to alter the asset's structural, long-term trajectory. Psychological Support & Buying Pressure: Because the golden cross is one of the most famous technical indicators, it acts as a self-fulfilling prophecy. When it appears, automated trading algorithms, institutional investors, and retail traders often flood the market with buy orders, driving the price higher. Shift in Support Levels: Once the cross occurs, the 200-day moving average typically transitions from a level of resistance (capping price gains) into a strong level of support (preventing the price from falling further).

$COYA picked up another 10,000 shares today. About to come in for something very significant.

$COYA BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $16 price target.

$COYA added another 1,400 shares. Unconcerned about short-term price action, holding to BO or PDUFA.

$COYA Kinda quiet. Should stay that way unless word starts to leak out between medical buddies. (wink, wink) Then the benefits of a small float will be apparent.

$COYA Added. Pullback on low volume & market conditions. Strong partnership with Dr. Reddy, plenty of cash, no debt, no warrants. Not too easy to find a biotech with such strong fundamentals.

$COYA IF $COYA averages $4.80 over the next 4 days of trading the GOLDEN CROSS WILL HAPPEN!! Again very rare happens .3% of the time!

$COYA Yesterday at. The close 43K at 4.99. It looks like someone knew something we don’t know yet.